Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS

Journal of Pharmaceutical and Biomedical Analysis

Volumn 26, Issue 4, 2001, Pages 637-650

  Bramer, Steven L ^a   Tata, Prasad N V ^a   Vengurlekar, Shailesh S ^b   Brisson, Jerry H ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b ABC Laboratories Incorporated   (United States)

Author keywords

Cilostazol; Human plasma; LC MS MS

Indexed keywords

3,4 DIHYDRO 6 [4 [1 (4 HYDROXYCYCLOHEXYL) 1H TETRAZOL 5 YL]BUTOXY] 2(1H) QUINOLINONE; CILOSTAZOL; DEHYDROCILOSTAZOL; DRUG METABOLITE; OPC 3930; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PLASMA; PRIORITY JOURNAL; RELIABILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; PLATELET AGGREGATION INHIBITORS; TETRAZOLES;

EID: 0034893475     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(01)00436-8     Document Type: Article

References (6)